2Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events.PREVENT Investigators. Circulation, 2000, 102:1503 - 1510.
3Simon A, Gariepy J, Moyse D, et al. Differential effects of nifedipine end co-amilozide on the progression of early carotid wall changes.Circulation, 2001, 103:2949 -2954.
4Zanchetti A, Bond MG, Hennig M, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis:principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation, 2002,106:2422 - 2427.
5Lubsen J, Wagener G, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial J Hypertens, 2005, 23:641 -648.
6Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA, 2004, 292:2217 -2225.
7Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension.Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens, 1998, 16:1823 - 1829.
8Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur)Trial Investigators. Lancet, 1997, 350:757 -764.
9Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and betablockers on cardiovascular morbidity and mortality in hypertension:the Nordic Diltiazem (NORDIL) study. Lancet, 2000, 356:359 - 365.
10ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 2002, 288:2981 -2997.
同被引文献21
1陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2010:282.
2SEHIFFRIN E L. Vascular endothelin in hypertension [J]. Vascul Pharmacol, 2005, 43(1) : 19-29.
3SHIN J, LEE J U, KIM K S, et al. Influence of abdominal circumference on the inappropriateness of left ventricular mass and diastolic funcfion in non-obese pat ents [J]. J Cardiol, 2007, 49(6): 323-329.
4BESTEHORN K, WAIILE K, KIRCH W. Stroke risk screening of adults with hypertension : prospective cross-sectional study in primary care[J]. Clin Drug Invest, 2008, 28(5) : 281-289.
5MARUTHUR N M, WANG N Y, APPEL I, J. Lifestyle interventions reduce coronary heart disease risk: resuhs from the PREMIER Trial [J]. Cireulation, 2009, 119 ( 15 ) : 2026- 2031.
6LIU L, ZHANG Y, LIU G, et al. The Felodiping Event Reduction (FEVER) study: a randomized long-term placebo- controlled trial in Chinese hypertensive patients[J]. J hypertens, 2005, 23(12) : 2157-2172.
7LIP G Y. Hypertension,platelets,and the endothelium:the "thrombotic paradox"of hypertension (or "Birmirlgham paradox" ) revisited [J]. Hypertension. 2003, 41 (3) : 199-200.
8CANTOR E J, MANCINI E V, SETH R, et al. Oxidative stress and heart disease:cardiac dysfunction, nutrition, and gene therapy [J]. Curr Hypertens Rep, 2003, 5 (2): 215- 220.
9WALLACE S M, YASMIN L, MCENiERY C M, et al. Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction[J]. Hypertension, 2007, 50( 1 ) : 228-233.
10HIROOKA Y, KIMURA Y, SAGARA Y, et al. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension[J]. Clin Exp Flypertens, 2008,30(3 ) : 267-276.
